Immunotherapy and Tumor Microenvironment Targeting: Nanomedicine for Precision Therapy of Triple Negative Breast Cancer
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 2638
Special Issue Editor
Special Issue Information
Dear Colleagues,
Triple negative breast cancer (TNBC) is characterized by its most aggressive behavior among other breast cancer subtypes. Immunotherapy has recently revolutionized cancer treatment, providing unprecedented clinical benefits. Among all breast cancers, TNBC is the most immunogenic subtype with a clear association with tumor-infiltrating lymphocytes, making it potentially amenable to specific immunotherapy classes. While immunotherapy has offered promising results in TNBC, most patients do not respond due to resistance to therapy and experience immune-related adverse effects due to their lack of specificity. Furthermore, the tumor microenvironment (TME) plays a central role in resistance to therapy and tumor progression in TNBC. Various components shape the TME, including cancer-associated fibroblasts (CAFs), endothelial cells, adipocytes, mesenchymal stem cells (MSCs), macrophages, vessels, pericytes, and extracellular matrix (ECM). The crosstalk between cancerous cells and TME enables tumor progression and transformation from in situ to an invasive phenotype. The use of nanotechnology-based platforms to deliver immunotherapeutic and TME-targeted agents or, a combination of all, could offer a significant advantage over conventional anticancer treatments. The clinical potential of combined nanotechnology/immunotherapy has recently been confirmed in the treatment of advanced TNBC. This special issue is designed to provide an insight into the most advanced nanomedicine/immunotherapy-based technologies that can enhance the precision therapy of TNBC, an unmet medical condition.
Dr. Pegah Varamini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- nanomedicine
- TNBC
- TME
- chemotherapy
- breast cancer
